Table 1 Characteristics of included studies
Study | Country | Study design | Gender (F/M) | Age (years ± SD) | Involved joints (PJI/total) | Sites of arthroplasty | Disease spectrum | Comorbidities * | Cutoff |
|---|---|---|---|---|---|---|---|---|---|
D-dimer | |||||||||
Qin et al. [11] | China | P | 69/53 | 65.21 ± 10.51 | 55/122 | Hips and knees | Chronic PJI + aseptic | Excluded | 1170 ng/ml |
Xiong et al. [13] | China | P | 48/32 | 61.60 ± 12.22 | 26/80 | Hips and knees | PJI + aseptic | Excluded | 756 ng/ml |
Shahi et al. [12] | USA | P | 94/101 | 62.46 | 57/195 | Hips and knees | Primary arthroplasty + PJI + aseptic + reimplantation | Not excluded | 850 ng/mL |
Xu et al. [14] | China | R | NM | NM | 82/224 | Hips and knees | PJI + aseptic | Excluded | 1020 ng/mL |
Huang et al. [8] | China | R | 46/34 | 67.15 ± 2.64 | 31/101 | Hips and knees | Primary arthroplasty + PJI + aseptic | Excluded | 850 ng/mL |
Pannu et al. [10] | USA | R | 62/49 | 68.89 ± 10 | 49/111 | Hips and knees | PJI + aseptic | NM | 2300 ng/mL |
Hu et al. [7] | China | R | 41/36 | 63.08 | 40/77 | Hips and knees, 2 others | PJI + aseptic | Not excluded | 955 ng/ml |
Li et al. [15] | China | R | NM | NM | 76/439 | Hips and knees | PJI + aseptic | Excluded | 1250 ng/ml |
Wu et al. [17] | China | R | 82/54 | 66.32 ± 11.73 | 35/116 | Hips and knees | PJI + aseptic+reimplantation | Not excluded | 410 ng/ml |
Fibrinogen | |||||||||
Li et al. [15] | China | R | NM | NM | 76/439 | Hips and knees | PJI + aseptic | Excluded | 4.01 g/L |
Wu et al. [17] | China | R | 82/54 | 66.32 ± 11.73 | 35/116 | Hips and knees | PJI + aseptic+reimplantation | Not excluded | 3.61 g/L |
Klim et al. [16] | Austria | P | NM | 65.50 ± 15.31 | 78/124 | Hips and knees | PJI + aseptic | Excluded | 5.19 g/L |
Xu et al. [9] | China | R | NM | NM | 153/360 | Hips and knees | PJI + aseptic | Excluded | 3.57 g/L |